Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 weeks, on patients with mild Thyroid-Associated Ophthalmopathy (TAO).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Clinical diagnosis of Thyroid-associated ophthalmopathy

• Mild TAO

• Normal serum free thyroxine and free triiodothyronine concentrations

• No previous specific therapy for TAO, except for local measures

• Written informed consent is obtained

Exclusion Criteria:

• Pregnant females as determined by positive (serum or urine) hCG test at screening or prior to dosing, or lactating females

• Uncontrolled diabetes or hypertension

• History of mental / psychiatric disorder

• Hepatic dysfunction (Alb, AST, ALT and Alkaline phosphates levels must be within normal range for eligibility)

• Renal impairment (Urea and Creatinine levels must be within normal range)

• Tetracycline allergy or intolerance